| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/24/2005 | US20050063997 Mixture of macrolactone antibodies and mycophenolic acid ; antiinflammatory agents; antiproliferative agents; topical drug |
| 03/24/2005 | US20050063996 Ocular solutions |
| 03/24/2005 | US20050063993 For treatment of cancer/tumors/fungal/viral infections; tumor associated antigens; genetic engineering |
| 03/24/2005 | US20050063991 administrating. to a diabetic or arteriosclerosis patient an effective amount of crude Dunaliella powder containing an approximately 1:1 ratio of all-trans and 9-cis beta -carotene |
| 03/24/2005 | US20050063990 Compositons and methods for weight loss |
| 03/24/2005 | US20050063980 An alginate, a pectin and an antacid, such as sodium or potassium bicarbonate; gastrointestinal reflux disease |
| 03/24/2005 | US20050063971 Monoclonal or humanized antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, polypeptide fragment, polynucleotide or antibody |
| 03/24/2005 | US20050063969 Assay |
| 03/24/2005 | US20050063965 Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes |
| 03/24/2005 | US20050063943 Conjugated of hydroxyalkyl starch and an active agent |
| 03/24/2005 | US20050063917 Solid oral compositions |
| 03/24/2005 | US20050063911 Accurate metered single inhalation administration |
| 03/24/2005 | US20050063909 Drug and adverse-effect agent coated with inner acid-soluble layer and outer base-soluble layer; sustained release; multilayer tablets; for treatment of pain with opiod analgesics |
| 03/24/2005 | US20050063905 Administering a RADIONUCLIDE COMPLEXED WITH A CHELATING AGENT SUCH AS MACROCYCLIC AMINOPHOSPHONIC ACID, or tetraazacyclododecanetetramethylenephosphonic acid (DOTMP); polycythemia vera, macroglobulinemia (Waldenstrom syndrome), megakaryocytic myelosis, malignant histiocytosis |
| 03/24/2005 | US20050061678 Treatment of humans with colloidal silver composition |
| 03/24/2005 | DE10341233A1 Composition, useful to treat e.g. atrial fibrillation, atrial flutter and atrial arrhythmia, comprises at least one beta-blocker and at least one compound of a phenylcarboxylic acid amide derivative |
| 03/24/2005 | DE10339157A1 Use of histamine antagonists against itching in outer auditory canal, especially by topical application |
| 03/24/2005 | DE10338174A1 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease |
| 03/24/2005 | DE10337905A1 Using apoptosis-regulating agent for treating disease, e.g. neurodegeneration or autoimmune diseases, acts by modifying interaction of mitochondrial potassium channels with apoptosis inducers |
| 03/24/2005 | DE10337904A1 Using apoptosis-inducing or stimulating agent for treating disease, particularly infections or tumors, acts by interaction with mitochondrial potassium channels |
| 03/24/2005 | CA2539000A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 03/24/2005 | CA2538755A1 Granular jelly drink capable of masking bitterness |
| 03/24/2005 | CA2538416A1 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug. |
| 03/24/2005 | CA2538412A1 Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
| 03/24/2005 | CA2538333A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 03/24/2005 | CA2538009A1 Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias |
| 03/24/2005 | CA2537820A1 Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins |
| 03/24/2005 | CA2537663A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 03/24/2005 | CA2533926A1 Methods and compositions for producing antigenic responses |
| 03/23/2005 | WO2005030935A2 Adjuvant activities of mutants of lt-iia and lt-iib enterotoxin lacking binding to ganglioside |
| 03/23/2005 | EP1517144A2 Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor |
| 03/23/2005 | EP1516881A2 Composition and method for modulating dendritic Cell-T cell interaction |
| 03/23/2005 | EP1516877A1 Amine derivatives as protease inhibitors |
| 03/23/2005 | EP1516639A1 Device in the treatment of pulmonary vasoconstriction and asthma |
| 03/23/2005 | EP1516617A2 Use of a thiazolidinedione for reducing apoptosis of pancreatic beta cells |
| 03/23/2005 | EP1516616A1 A controlled-release preparation having specific pore forming agents in the coating |
| 03/23/2005 | EP1516614A1 Method of preparing particles for agglomeration |
| 03/23/2005 | EP1516597A1 Drug eluting stent |
| 03/23/2005 | EP1516190A1 Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor |
| 03/23/2005 | EP1516064A2 Methods of using 46828, a human acyl-coa synthetase |
| 03/23/2005 | EP1516061A1 Method for identifying agonists or antagonists for the gpr45-like/gpr63 receptor |
| 03/23/2005 | EP1516047A1 Purified pkb ser 473 kinase and uses thereof |
| 03/23/2005 | EP1515982A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 03/23/2005 | EP1515974A2 Novel maxi-k channel blockers, methods of use and process for making the same |
| 03/23/2005 | EP1515968A2 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 03/23/2005 | EP1515965A1 Phenylaminopyrimidines and their use as rho-kinase inhibitors |
| 03/23/2005 | EP1515753A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
| 03/23/2005 | EP1515750A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 03/23/2005 | EP1515749A1 Combined use of a modulator of cd3 and a glp-1 compound |
| 03/23/2005 | EP1515748A2 Anti-estrogen and immune modulator combinations for treating breast cancer |
| 03/23/2005 | EP1515747A2 Immunogenic agent therapy using plasmapheresis or exchange transfusion |
| 03/23/2005 | EP1515743A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 03/23/2005 | EP1515731A1 Anti-spasmodic comprising xenon |
| 03/23/2005 | EP1515730A1 Novel maxi-k channel blockers, methods of use and process for making the same |
| 03/23/2005 | EP1515725A2 Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions |
| 03/23/2005 | EP1515724A1 Mitotic kinesin inhibitors |
| 03/23/2005 | EP1515722A2 Ophthalmic compositions for treating ocular hypertension |
| 03/23/2005 | EP1515721A1 Ophthalmic compositions for treating ocular hypertension |
| 03/23/2005 | EP1515720A1 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions |
| 03/23/2005 | EP1515719A2 Enhancing treatment of mdr cancer with adenosine a3 antagonists |
| 03/23/2005 | EP1515718A2 Modulation of activation of glucocorticoid receptors by breakdown products of glucocorticoids |
| 03/23/2005 | EP1515712A2 Use of taurine for the treatment of alopecia |
| 03/23/2005 | EP1515709A2 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder |
| 03/23/2005 | EP1515708A1 Combinations of pde-v inhibitors and nk1 antagonists for the treatment of depression |
| 03/23/2005 | EP1515707A2 Method of treating atherosclerosis and other inflammatory diseases |
| 03/23/2005 | EP1515701A1 Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| 03/23/2005 | EP1515698A2 Liposomes containing biologically active compounds |
| 03/23/2005 | EP1515674A1 Abuse-resistant opioid solid dosage form |
| 03/23/2005 | EP1515615A1 Nutritional composition for detoxification and cancer prevention |
| 03/23/2005 | EP1515607A2 Antimicrobial compositions, products and methods employing same |
| 03/23/2005 | EP1345618B1 Chlorzoxazone for the treatment of psoriasis |
| 03/23/2005 | EP1328268B1 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 03/23/2005 | EP1280528B1 R-eliprodil for treating glaucoma |
| 03/23/2005 | EP1272218B1 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 03/23/2005 | EP1152764A4 Compositions and methods for use in targeting vascular destruction |
| 03/23/2005 | EP1100469B1 Rapidly disintegrable solid preparation |
| 03/23/2005 | EP1045832B1 Novel urethanes, thio and dithio analogues, the salts thereof, medicaments containing said compounds, use and method for the production thereof |
| 03/23/2005 | EP0723398B1 Superoxide dismutase mimetics |
| 03/23/2005 | CN1599792A Nutrient medium for maintaining neural cells in injured nervous system |
| 03/23/2005 | CN1599752A Nucleic protein 'Shoca'-a component of wnt signal transmission channel |
| 03/23/2005 | CN1599750A Cytotoxic protein and utilization thereof |
| 03/23/2005 | CN1599744A Beta -2'-or 3'-halonucleosides |
| 03/23/2005 | CN1599734A 3, 4-di-substituted maleimide compounds as CXC-chemokine receptor antagonists |
| 03/23/2005 | CN1599731A Benzothiazepine derivatives |
| 03/23/2005 | CN1599729A HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 03/23/2005 | CN1599728A 1, 2, 4-triazole derivatives containing a sulphamate group as aromatase inhibitors |
| 03/23/2005 | CN1599724A Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 03/23/2005 | CN1599627A Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| 03/23/2005 | CN1599626A Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 03/23/2005 | CN1599625A Use of an h1 antagonist and a safe steroid to treat rhinitis |
| 03/23/2005 | CN1599623A Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 03/23/2005 | CN1599622A Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease |
| 03/23/2005 | CN1599620A Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and prod |
| 03/23/2005 | CN1599619A Methods and compositions for treating dermal lesions |
| 03/23/2005 | CN1599618A Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/23/2005 | CN1599614A Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 03/23/2005 | CN1599613A Combinations for the treatment of immunoinflammatory disorders |
| 03/23/2005 | CN1599612A Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 03/23/2005 | CN1599609A Combination of a selective PDE4 inhibitor and an adrenergic beta-2 receptor agonist |
| 03/23/2005 | CN1599606A Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |